Helious Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 8 Months
- Last Filing with ROC 31 Mar 2019
- Revenue Growth -46.86%
- Profit Growth -4600.00%
- Ebitda -4539.44%
- Net Worth -135.59%
- Total Assets -31.22%
About Helious Pharma
Helious Pharma Private Limited (HPPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 14 June 2017 (Seven years and eight months 10 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ramdeo Mehata and Ravishankar Mehta serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51909DL2017PTC319211
- Company No.
319211
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Jun 2017
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
What products or services does Helious Pharma Private Limited offer?
Helious Pharma Private Limited offers a wide range of products and services, including Common Disease Medicines, Cough Syrup, Ayurvedic Health Tonic, Herbal Uterine Tonic, Protein Powder, Chocolate Protein Powder, Ayurvedic,Herbal Products & Medicine, Ayurvedic Medicine.
Who are the key members and board of directors at Helious Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ravishankar Mehta  | Director | 14-Jun-2017 | Current |
| Ramdeo Mehata | Director | 14-Jun-2017 | Current |
Financial Performance of Helious Pharma.
Helious Pharma Private Limited, for the financial year ended 2019, experienced significant reduction in revenue, with a 46.86% decrease. The company also saw a substantial fall in profitability, with a 4600% decrease in profit. The company's net worth observed a substantial decline by a decrease of 135.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Helious Pharma?
In 2019, Helious Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Helious Pharma?
Unlock and access historical data on people associated with Helious Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Helious Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Helious Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.